Yep, the share was undervalued last week at 18 cents and it remains undervalued today at 26 cents, all within the given intensity of future brightness.
A deal with a multinational partner is likely to materialise well before the middle of the year if it is to generate sales within the year. There is a lot more work to do to make commercial sales a reality. If sales are expected within this calendar year, they need a deal inked early in the 2nd quarter at the latest, preferably in Q1. This may be closer than we know.
Ann: PolyNovo's US FDA approval, page-31
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |